Amyotrophic lateral sclerosis (ALS) is a progressive disease that attacks the motor neurons in the nervous system and causes acute disability. It is also known as Lou Gehrig’s disease, after the American baseball player who was famously diagnosed with the condition. We’ve compiled a list of some of the most…
Search results for:
Reldesemtiv is an investigational oral treatment that has been tested in clinical trials for treating amyotrophic lateral sclerosis (ALS).
AstroRx is an investigational cell-based therapy that is being tested in early clinical trials for amyotrophic lateral sclerosis (ALS). It aims to slow ALS progression by preventing further damage to nerve cells.
Arimoclomol is an oral therapy that has been tested in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS), but its development has been discontinued for this indication.
A number of treatment options exist for amyotrophic lateral sclerosis (ALS), a disease marked by the progressive loss of motor neurons — specialized nerve cells that control muscle movements — and symptoms like muscle weakness and wasting.
CNM-Au8 is an experimental oral therapy being tested as a potential treatment for people with amyotrophic lateral sclerosis (ALS).
While a link between neurodegenerative diseases and cancer seems unlikely, a recent study suggests that such connections might exist. Genetic analysis of amyotrophic lateral sclerosis (ALS) patients, conducted by Japanese and Taiwanese researchers, revealed that many genes linked to ALS are also related to certain cancers. The research suggests that…
Social Clips
Explaining Amyotrophic Lateral Sclerosis
This very informative video from Khan Academy explains more about the progressive, degenerative disease, amyotrophic lateral sclerosis (ALS). MORE: 10 things to know about genetic testing for ALS. The film explains that ALS is a rare disease that affects one to two people out of every 100,000. The…
News
Masitinib Phase 3 Trial Data Show Slowed Amyotrophic Lateral Sclerosis Progression, AB Science Says
French biotech company AB Science presented the results of the Phase 3 clinical trial for its lead compound masitinib, which showed effectiveness in improving the functioning of patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The randomized, double-blind clinical trial (NCT02588677) compared the efficacy and…
Social Clips
What is Amyotrophic Lateral Sclerosis?
Learn all about amyotrophic lateral sclerosis (ALS) in this video from Karalyn Pappas. Learn more about ALS here: https://bit.ly/ALSNewsToday…